WAP
UTHR icon

Wealthcare Advisory Partners’s United Therapeutics UTHR Stock Holding History

Wealthcare Advisory Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-350
Closed -$208K – 1153
2026
Q1 		$208K Buy
+350
New +$174K ﹤0.01% 1014
2021
Q2 		– Sell
-2
Closed – – 1797
2021
Q1 		$0 Buy
+2
New +$333 ﹤0.01% 2115

Other funds holding UTHR

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealthcare Advisory Partners's UTHR Position: Q2 2026 in Review

Wealthcare Advisory Partners sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 350 shares — an estimated $208K sold.

Wealthcare Advisory Partners first reported a position in UTHR in Q1 2021 and held it in 2 quarters. The position peaked at $208K in Q1 2026. 109 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Wealthcare Advisory Partners reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 350 United Therapeutics shares in Q2 2026, an estimated $208K.
  • Wealthcare Advisory Partners first reported a position in United Therapeutics in Q1 2021 and held it in 2 quarters.
  • Wealthcare Advisory Partners's United Therapeutics position peaked at $208K in Q1 2026.
  • 109 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.